Lineu A.

Full P&L ownership for Surgery, Urology & Critical Care (USD 15M), managing 3 Sales Managers, 3 Product Managers, and 25+ professionals. FY26 tracking +68.6% vs. PY. • Redesigned GTM strategy, sales team structure, and distribution network — closing FY25 with +4.5% revenue growth vs. PY, 25 points ahead of the inherited trajectory • Launched GalaFLEX in Brazil, developed national distribution network and a dedicated 13+ person team — 81% above budget in Q1 FY26 • Partnered with BCG on a market expansion case, securing Executive LT approval to scale Plastic and Reconstructive Surgery platform revenue projection from USD 790K to USD 3M in FY26 • Improved conversion from 4.4%→18.6% and win rate 46.8%→73.7% via Salesforce pipeline management

Regional strategy for Surgery across 4 LATAM hubs, leading Hernia, Infection Prevention, and Biosurgery platforms. Led BU growth from USD 17M to USD 31M (>80% over two years). • Launched Phasix across 5 markets, rolled out Sterile Chloraprep region-wide, and integrated the Tissuemed portfolio post-acquisition • Indirectly led 4 country-level Product Managers and served on the LATAM Leadership Team, owning P&L, portfolio strategy, pricing, and global-platform alignment • Won the S.A.R.A. Award and reached BD’s Top 3 Global Marketing Awards with a Phasix market access project in Mexico

Led commercial strategy for Brazil across Coronary, Endovascular, and Interventional Oncology (USD 18M), managing a team of 5 KAMs, 2 Sales Executives, and 2 Product Specialists. • Navigated a challenging macro environment — inflation, currency devaluation, market consolidation, and price pressure — by shifting the commercial model toward direct sales to protect ASPs and improve profitability • Developed a differentiated value proposition for the portfolio, positioning Terumo as the preferred end-to-end provider for Interventional solutions across key accounts • Launched Ultimaster Tansei coronary stent as a niche bifurcation device, differentiating against major competitors through a targeted medical education strategy and structured KOL engagement • Negotiated with payors to secure price increases, defending portfolio margins across priority accounts

• Launched Interventional Cardiology and Endovascular portfolios across Brazil, Argentina, and Mexico. • Built distributor networks and Centers of Excellence to drive therapy adoption. • Led pricing and positioning strategy; organized multiple medical education events.

• Managed Spine, Trauma, Biologics, and MTS portfolios; led team of 3. • Achieved 20% inventory reduction and improved forecast accuracy. • Supported OLIF expansion and channel conversion strategies. • Managed relationship with KOLs from Brazil and Latin America.

• Delivered 87% YoY sales growth through GTM redesign and distribution network expansion. • Led pricing strategy and launched key therapy; received FY18 Channel Management Award. • Successfully launched OLIF during the fiscal year. • Indirect management of 5 sales representatives. • Award won: Indirect Channel Management, FY18.

• Developed training and marketing materials to support the sales force. • Trained 160+ sales professionals; conducted 10+ education events. • Redesigned both demand planning and supply execution processes to ensure alignment with the sales plan. • Interim management of Spine BU; drove 60% YoY sales growth.

• Redesigned internal processes aiming to improve service level to all stakeholders; led team of 2. • Deployed and managed distributor network across 20+ countries; led CE marking project. • Achieved 107% CAGR over 3 years through strategic launches and pricing initiatives.

Numero Uno Award, 2012

Joined Johnson & Johnson Medical through a corporate development program for young professionals, working along with the product manager for Ethicon.